Abstract
To examine the cost of incident cases of non-small-cell lung cancer (NSCLC) in a commercially insured cohort. Claims from Virginia Blue Cross and Blue Shield (BCBS) beneficiaries with lung cancer from 1989 to 1991 were merged with records from the Virginia Cancer Registry (VCR). Data from the VCR identified incident cases, stage, and type of cancer at diagnosis. Costs for all medical care included insurance payment, copayments, and deductibles for 2 years after diagnosis or until death. Three hundred forty-nine incident NSCLC patients were evaluated. The mean 2-year cost for each patient after diagnosis or until death was $47,941 (95% confidence interval, $43,758 to $52,124). Total average costs and hospital days were significantly lower for local disease ($37,514, 21.2 days), but were similar for regional ($52,797, 30.0 days) and distant ($49,382, 33.0 days) disease. Hospital days accounted for 48% and hospital-based claims for 70% of costs. Initial treatments, which included radiation, unadjusted for stage, had the lowest survival rates and the highest costs, and were associated with the most hospital days. Initial stage, race, gender, and age were not predictors of total 2-year costs. The independent predictors of total 2-ye...Continue Reading
Citations
Jul 2, 2004·Disease Management : DM·J Russell Hoverman, S Marciann Robertson
Feb 22, 2008·AJR. American Journal of Roentgenology·James G RavenelGerard A Silvestri
Sep 4, 2015·Palliative Medicine·Karen E BremnerK Robin Yabroff
May 4, 2001·Cancer·B E HillnerS S Agarwala
Aug 21, 2003·Postgraduate Medicine·Joel J Bechtel, Thomas L Petty
Jun 17, 2003·PharmacoEconomics·Anne-Chantal BraudIsabelle Durand-Zaleski
Oct 30, 2007·Nature Clinical Practice. Oncology·K Robin YabroffMartin L Brown
Apr 4, 2017·Cancer Investigation·Li-Fang ZhouLue Ping Zhao
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GaynonH N Sather
Apr 15, 2006·Palliative Medicine·Tiina PodymowDoug Coyle
Mar 22, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Thomas N Chirikos
Apr 8, 2004·Journal of Clinical Pharmacy and Therapeutics·M Ranson, S Wardell
Jan 22, 2004·British Journal of Cancer·C ChouaïdA Vergnenègre
Oct 27, 2010·Journal of Evaluation in Clinical Practice·Eva PaganoGiovannino Ciccone
Jul 7, 2005·Journal of Medical Internet Research·Cathy J Bradley